Materials and Methods
gous hemoglobinopathies;for heterozygous hemoglobinopathies and Hb synthesis variants, HbA1C should be expressed as percentage of HbA0 + HbA1; abnormal Hbs are usually recognized; both carbamylated-and acetyIated-Hbs interfere and Schiff base must be eliminated. Except for stored blood,allHb variants and derivatives gave erroneous results with disposable ion-exchange columns. Dako #{149} Control Hb; erythrocytes were washed, hemolyzed, and lyophilized in vials, as previously described (5).
Materials and Methods

Samples
#{149} Carbamylated-Hb; erythrocytes were washed and hemolyzed, followed by synthesis of carbamylated-Hb (7) and lyophilization in vials (5) . Formation of carbamylated-Hb was confirmed by J. Barron and E. Carr, using their previously described HPLC method (8) .
#{149} Acetylated-Hb; erythrocytes were washed, hemolyzed, followed by synthesis of acetylated-Hb (7) and lyophilization in vials (5) . Formation of acetylated-Hb was confirmed by U. Turpeinen Figure 1 ). Mean glyco-Hb percentages of this subject, as obtained by different methods, are given in Table 2 ("control").
Homozygous
HbS. By affinity chromatography, the sample from the patient with HbSS yielded low, but variable, glyco-Hb percentages (Figure 1 -lives: 27-36,5-10, and 19 days, respectively) (11) will show decreased glyco-Hb percentages that do not relate to mean blood glucose content, unless special reference ranges are used. Specific measurements of HbAic in homozygous hemoglobinopathies will obviously fail to detect glyco-Hb in these conditions, and will instead necessitate measurements of HbX1 (e.g., HbS1C and HbC1). Expression of HbA1C in terms of total Hb will lead to underestimation of glyco-Hb percentages in conditions characterized by the presence of high percentages of Hb other than HbA0, such as in subjects with heterozygous hemoglobinopathies (e.g., HbAE, HbAS, and HbAC) or subjects with Hb synthesis variants (e.g., f3-thalassemia and HPFH). Measurements of the appropriate derivative/(precursor + derivative) ratios-in general: HbX1,/(HbX0 + HbX1)-may overcome these problems. Usefulness of special reference ranges for HbA10/total Hb ratios in subjects with heterozygous hemoglobinopathies and a-chain synthesis-variants seems questionable, because of the variability of abnormal Hb expression [e.g., the frequent occurrence of concomitant a-thalassemia in subjects of African descent with HbAS (3)] and variability of p-chain expression (e.g., thalassemia major and minor), respectively. Both Hb variants and Hb derivatives may, depending on the technique used, lead to analytical interferences with glyco-Hb. yses of the Scbiff base are most probably caused by decreased glyco-Hb recovery, owing to competition of the abnormally high amounts of glucose added to the sample.
HPLC
Most HPLC methods will recognize abnormal Hbs in the profile. HPLC is obviously unsuitable for measurement of HbA10 in subjects with HbSS and HbCC. Mea 
